Biomarkers key to better cancer trials

Joseph Nevins, director of the of the Duke Institute for Genome Sciences and Policy's Center for Applied Genomics & Technology, believes it's time to radically change the way that cancer drugs are developed if we expect to see a new generation of personalized therapies. Because of the complexity of cancer--breast cancer, he speculates, could be broken down into 15 different types of cancers - tissue samples should be collected from patients going through clinical trials so that more effective biomarkers can be developed to match a new treatment with a patient. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.